EX-23.2 2 acer_ex23-2.htm CONSENT OF WOLF & COMPANY, P.C., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Untitled Document
 
Exhibit 23.2
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in this Post-Effective Amendment to the Registration Statement (No. 333-208314) on Form S-3 and related Prospectus of Acer Therapeutics Inc. of our report dated March 22, 2017, except for Note 11 as to which the date is July 19, 2017, relating to the consolidated financial statements of Acer Therapeutics Inc., appearing in the Registration Statement (No. 333-219358) on Form S-4, as amended, and related prospectus of Acer Therapeutics Inc. (formerly known as Opexa Therapeutics, Inc.)
 
We also consent to the reference to our firm under the heading "Experts" in such Prospectus.
 
/s/ Wolf & Company, P.C.
Wolf & Company, P.C.
Boston, Massachusetts
November 14, 2017